DBD Diebold Nixdorf Forecast, Technical & Fundamental Analysis

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DBD's RSI Indicator exited the oversold zone, 8 of 11 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for DBD just turned positive on October 01, 2026. Looking at past instances where DBD's MACD turned positive, the stock continued to rise in 25 of 32 cases over the following month. The odds of a continued upward trend are 78%.

Following a +3.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where DBD advanced for three days, in 173 of 218 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

DBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 44 cases where DBD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.

The 50-day moving average for DBD moved below the 200-day moving average on September 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.

The Aroon Indicator for DBD entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.133) is normal, around the industry mean (51.922). P/E Ratio (20.162) is within average values for comparable stocks, (82.636). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.135). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.606) is also within normal values, averaging (70.810).

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. DBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 67 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.